• Celerion Newsletter
Belfast - Center of Excellence for Respiratory

Celerion

committed to service excellence

Primary Navigation for Celerion

  • Home
  • About Celerion
    • Why Celerion?
    • Mission, Vision and Credo
    • Management Team
    • Who We Work With
    • Locations
    • Environmental Sustainability
  • Applied Translational Medicine
    • Key Elements of Success
  • Services
    • Global Clinical Research
      • AAHRPP Accreditation
      • Phase I and lla Studies
      • In-hospital Beds
      • Study Experience
      • Belfast – Center of Excellence for Respiratory
      • Early Cardiac Services
      • Hybrid Phase I/ECG Core Lab
      • ADME/Mass Balance
      • Microtracer Studies
      • USP <797> Clean Room
      • ClinQuick® Electronic Data Acquisition
      • Recruitment
    • Clinical Pharmacology Sciences
      • Modeling and Simulation
      • Study Design and Protocol Development
      • Data Programming
      • Biostatistics
      • Pharmacokinetics/Pharmacodynamics (PK/PD)
      • Medical Writing and Reporting
      • Streamlined Data Flow Process
    • Global Bioanalytical Services
      • Small Molecule
      • Large Molecule
      • Electronic Laboratory Notebook System
      • ADME/Mass Balance
    • Drug Development Services
      • Biopharmaceutical Development
      • Program and Project Management
      • Regulatory Affairs
  • Celerion Europe
    • Global Clinical Research
    • Clinical Pharmacology Sciences
    • Global Bioanalytical Services
    • Management Team
  • The Biosimilars Alliance
    • The Biosimilars Alliance – Overview
    • The Biosimilars Alliance – Benefits
  • Case Studies
    • Global Clinical Research
      • Responding to an Unexpectedly High Drop Rate
      • Mass Balance Study
      • Semen Clinical Trials
    • Clinical Pharmacology Sciences
      • Partnering with Biotechnology Companies
      • Partnering with Large Pharmaceutical Companies
      • Protocol Study Design and Development for Generic Studies
      • Difficult to Recruit Population
      • Consistent Database Structure for Programs of Studies
    • Global Bioanalytical Services
      • Improved Desmopressin Analysis of Clinical Samples
      • Optimized LC-MS/MS Method for New Observed Metabolite
      • Bioanalytical Support of Oncology Studies
      • High Throughput Bioanalytical Analysis
      • Partnering with Biotechnology Companies
      • Partnering with Pharmaceutical Companies
      • Development of an LC-MS/MS Peptide Method
    • Drug Development Services
      • Support of CMC to IND for Novel First-in-Class Small Molecule Drugs
      • Rapid Proof-of-Concept for Novel Drug Treatment for Rare Metabolic Disease
      • Proof-of-Concept Efficacy Clinical Study
      • European Biotechnology Company Seeking First-in-Human U.S. Clinical Study
      • Asian Biotechnology Company with CNS Compound
  • White Papers
  • Other Resources
  • News & Events
    • Press Room
    • Conferences
    • Symposia
    • Webinars
  • Participate in a Study
  • Careers
    • Message from the CEO
    • Culture
  • Spring 2013 Newsletter
  • Fall 2012 Newsletter
  • Spring 2012 Newsletter

News & Events

Webinars

Past Webinars

Spring 2012

Discerning Early Clinical Signals of Efficacy for Treating Respiratory Diseases

Apr 24, 2012

This webinar addressed advances in the development of drugs to treat respiratory diseases with a focus on new technologies that enrich data collected early in clinical research.  Prof. Stuart Elborn, Queen’s University, Belfast is a leading researcher in pulmonary function assessments and biomarkers for chronic infections that impact patients with respiratory diseases such as cystic fibrosis, COPD and asthma. Complementing Prof. Elborn’s insights, Dr Stephen Smith addressed the logistical considerations in conducting these complex but data rich early clinical studies with new therapeutic agents.

Learn More      To view this webinar: Click Here

Challenges in Early Comparability Assessment of Biosimilars

Mar 20, 2012
The success of biologically-derived drug products has driven the demand for “biosimilar” versions of these products to increase competition and reduce costs to patients and providers.  However, these products are complex to manufacture.  Once an apparent source of drug substance has been established it is critical to understand whether its safety, immunogenicity, pharmacokinetics and pharmacodynamics are comparable to the innovator product before proceeding to expensive multi-center patient studies.

This webinar addressed the key elements of early biosimilar development that provide the bridge between the manufactured product and the larger clinical studies needed to prove comparable efficacy and safety.

Learn more      To view this webinar: Click Here

Spring 2011 Webinar Series: Optimizing Early Clinical Research to Accelerate Drug Development Timelines

Microtracer Studies
Jun 8, 2011

Micro-radiotracer studies in humans that take advantage of the very high sensitivity of Accelerator Mass Spectrometry (AMS) provide new approaches to answering important questions in early clinical drug development.

This webinar reviewed the requirements and practical considerations around preparation and parametric release of drug in a pharmacy clean room to be administered intravenously. In addition, the regulatory requirements around validation and quality control of AMS assays were reviewed. The audience had the opportunity to question experts involved in both parametric release of drug product and AMS analyses.

Learn More       To view this webinar please click here

Adaptive Study Design
May 17, 2011

Study designs for clinical pharmacology studies have become increasingly innovative. In this webinar, Celerion’s clinical pharmacology scientists described recent trends in adaptive designs, highlight areas where innovative approaches resulted in more robust clinical study results and discuss the challenges sometimes faced with these designs. Through case studies, the audience learned key advantages for using adaptive study designs in early clinical research, understand challenges for this approach and how to maximize the amount of information gained from data in the least amount of time.

Learn More       To view this webinar please click here

Value of Early Safety Assessments
Apr 28, 2011

In this webinar, Celerion’s experienced physicians described their approaches and experience in making the early assessments of safety and tolerability of new drug candidates. Through brief case studies, the speakers discussed changing tools, approaches and considerations for identifying hepatic, renal, pulmonary, neuropsychiatric and cardiovascular adverse effects, as well as assessing risk for ocular toxicity in humans.

Learn More       To view this webinar please click here

 

Fall 2010 Webinar Series: The Need for Speed

Employing Real-Time Strategies in the Bioanalysis Workspace
Nov 11, 2010

In this webinar, Celerion Bioanalytical Services scientists discussed how a couple of innovative approaches to bioanalytical science improved workflow and data delivery.

To view this webinar please click here

Science and Innovation Driving Efficient, Cost Effective QT Assessment
Oct 26, 2010

This webinar presented information on cost effective study designs and the evolution of cost effective ECG analysis strategies, including the increased use of Holters, greater automation in ECG process, QT interval measurement, and integration of Phase I and ECG Core Lab functions.

To view this webinar please click here

Enriching Early Clinical Studies for Better Data, Faster
Oct 7, 2010

In this webinar, Celerion partnered with Xceleron to discuss how Accelerator Mass Spectrometry (AMS) through measurement of ultra low levels of drug-associated radioactivity, can enrich the information gathered from early clinical studies.

To view this webinar please click here

See also…

Presentation: JSCPT 2011 – Enriching Phase I Studies for Better Decision Making

Presentation: PhUSE 2011 – Leveraging Biomarkers in Early Clinical Drug Development for Metabolic Disease Therapies

Scientific Poster: AAPS 2011 – Pharmacokinetic Data Submission in the CDISC Environment

For more information contact us

Footer Naviation

  • About
  • Locations
  • Careers
  • Request a Proposal
  • Contact
  • Privacy Policy
© 2013 Celerion